REDWOOD CITY, Calif.,
March 5, 2018 /PRNewswire/ -- AcelRx
Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty
pharmaceutical company focused on the development and
commercialization of innovative therapies for the treatment of
moderate-to-severe acute pain, today announced that that
Vincent J. Angotti, Chief Executive
Officer, will be presenting at the 30th Annual ROTH Conference, the
38th Annual Cowen Health Care Conference and the 28th Annual
Oppenheimer Healthcare Conference. Details of the events are as
follows:
30th Annual ROTH Conference
Date: Monday, March 12, 2018
Location: The Ritz-Carlton, Laguna
Niguel
Presentation Time: 1:00 pm PT
(4:00 pm ET)
38th Annual Cowen Health Care Conference
Date:
Wednesday, March 14, 2018
Location: The Boston Marriott Copley Place, Boston
Presentation Time: 8:40 am ET
(5:40 am PT)
28th Annual Oppenheimer Healthcare Conference
Date:
Wednesday, March 21, 2018
Location: The Westin New York Grand Central, New York
Presentation Time: 11:30 am ET
(8:30 am PT)
Presentations will be webcast live and can be accessed through
the Investors page at www.acelrx.com. For those not available to
listen to the live broadcast, a replay will be archived for 90 days
and available through the Investors page on www.acelrx.com.
About AcelRx Pharmaceuticals, Inc.
AcelRx
Pharmaceuticals, Inc. is a specialty pharmaceutical company focused
on the development and commercialization of innovative therapies
for the treatment of moderate-to-severe acute pain. AcelRx's
proprietary, non-invasive sublingual formulation technology
delivers sufentanil with consistent pharmacokinetic profiles. The
company has two product candidates including DSUVIA™
(sufentanil sublingual tablet, 30 mcg), known as DZUVEO outside
the United States, with a proposed
indication for the treatment of moderate-to-severe acute pain in
medically supervised settings, and ZALVISO® (sufentanil
sublingual tablet system, SST system, 15 microgram) being developed
as an innovatively designed patient-controlled analgesia (PCA)
system for reduction of moderate-to-severe acute pain in medically
supervised settings.
For additional information about AcelRx's clinical programs,
please visit www.acelrx.com.
View original content with
multimedia:http://www.prnewswire.com/news-releases/acelrx-pharmaceuticals-to-participate-at-three-upcoming-investor-events-in-march-300607717.html
SOURCE AcelRx Pharmaceuticals, Inc.